In 2007, Warburg Pincus invested in Lepu Medical (Lepu), a leading provider of interventional cardiology devices, drugs, and equipment including drug-eluting stents to treat heart diseases. Lepu leveraged Warburg Pincus’ expertise in sourcing and evaluating multiple acquisition targets, both in China and abroad. The Warburg Pincus team was instrumental in the restructuring of the company and its subsequent IPO. In 2009, Lepu became one of the first companies to list on ChiNext of the Shenzhen Stock Exchange, the growth enterprise stock exchange in China. Additionally, Warburg Pincus worked closely with Lepu’s management team on improving operational efficiency, management capability, and investor relations. Warburg Pincus exited the investment in 2013.
Website Case Studies Disclaimer
The investments described in the case studies are provided for illustrative purposes only and are not, and do not purport to be, representative of all investments, or all types of investments, previously made by Warburg Pincus, or indicative of the performance of all prior Warburg Pincus investments. The case studies have been selected on the basis of objective criteria that Warburg Pincus believes are representative of the firm’s experience partnering with portfolio company management teams, and of the sectors, stages, strategies and/or geographies in which the firm invests. The information provided in the case studies are not necessarily an indication of future results, and may not be relied up for any purpose. Warburg Pincus’ current or future portfolio companies may differ materially in size, type, performance and other characteristics from the investments presented in the case studies. Further, references in this case study should not be construed as a recommendation or offer to buy or sell any particular security or to make any particular investment.